# A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

> **NCT07477457** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 45 (estimated)

## Conditions studied

- Osteosarcoma
- Metastasis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Doxorubicin
- **DRUG:** Cisplatin
- **DRUG:** Gefitinib
- **DRUG:** Trametinib
- **DRUG:** Disulfiram
- **DRUG:** Sunitinib
- **DRUG:** Ifosfamide
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT07477457
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2028-03
- **Final completion:** 2028-03-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477457, "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07477457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*